Fosamax Managing Efficacy Plateau: When Alendronate Stops Working and What to Do Next

What an Alendronate Efficacy Plateau Actually Means

An efficacy plateau with alendronate describes the point where bone mineral density (BMD) stops increasing despite continued therapy. This is a pharmacologically expected phenomenon, not necessarily a treatment failure. Alendronate works by suppressing osteoclast-mediated bone resorption, and once resorption is maximally suppressed, further BMD gains slow or stop.

Distinguishing Plateau From Treatment Failure

The Fracture Intervention Trial (FIT) demonstrated that alendronate 5 mg and 10 mg daily reduced the risk of new vertebral fractures by 44% and hip fractures by 47% over 3 years in postmenopausal women with existing vertebral fractures (N=6,459). BMD at the hip increased by 4.1% at the femoral neck and 6.2% at the lumbar spine over that period.

The distinction matters. A patient whose BMD has stabilized at a higher level than baseline is still benefiting from fracture protection. The AACE/ACE 2020 clinical practice guidelines define treatment failure as either a new fragility fracture after 12 or more months of therapy, or a significant and persistent decline in BMD (typically greater than the least significant change on DXA, which is 3 to 5% at the lumbar spine).

When BMD Gains Typically Slow

Data from the FLEX trial (the FIT Long-Term Extension, N=1,099) showed that women who received alendronate for 10 years gained most of their BMD during the first 3 years at the hip and 5 years at the spine. After year 5, lumbar spine BMD continued to increase modestly (approximately 1.0% per year), while femoral neck BMD essentially plateaued.

Ruling Out Pseudo-Plateau: The Adherence and Absorption Problem

Before attributing a BMD plateau to drug exhaustion, clinicians must rule out correctable causes. Up to 50% of patients who appear to have stopped responding are actually experiencing poor adherence or inadequate drug absorption.

Adherence Is the Most Common Culprit

A 2004 analysis published in JAMA found that only 43% of patients prescribed oral bisphosphonates remained adherent at 1 year. Alendronate requires strict fasting administration (30 minutes before first food or drink, with 6 to 8 oz of plain water, remaining upright). Patients who take it with coffee, take it lying down, or simply forget doses may absorb as little as 0.6% of the oral dose instead of the already low bioavailability of approximately 0.7%.

Secondary Causes of Bone Loss

The Endocrine Society clinical practice guideline on osteoporosis recommends evaluating for secondary causes before concluding that a bisphosphonate has failed. These include:

• Vitamin D insufficiency (25-hydroxyvitamin D <30 ng/mL)
• Undiagnosed celiac disease or other malabsorption
• Primary hyperparathyroidism
• Hyperthyroidism or overreplacement with levothyroxine
• Glucocorticoid use (even inhaled corticosteroids at high doses)
• Excessive alcohol consumption

A basic workup includes serum 25-hydroxyvitamin D, PTH, calcium, TSH, CBC, comprehensive metabolic panel, and 24-hour urine calcium. Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research and Osteoporosis Center, has stated: "The most common reason for apparent bisphosphonate failure is something we can fix without changing the drug."

Bone Turnover Markers as a Compliance Check

Serum C-terminal telopeptide (CTX) can confirm whether alendronate is actually suppressing bone resorption. A CTX value below 150 pg/mL suggests adequate suppression. Values above 300 pg/mL while the patient is supposedly on therapy point toward nonadherence or malabsorption rather than a true pharmacologic plateau.

How to Titrate Fosamax: Dose Adjustment Options

Alendronate is FDA-approved at two doses for osteoporosis treatment: 10 mg daily or 70 mg weekly. There is no FDA-approved "dose escalation" pathway, but clinical strategies exist.

The 10 mg to 70 mg Conversion

Some patients are started on 10 mg daily and later switched to 70 mg weekly for convenience. These are pharmacokinetically equivalent in terms of cumulative weekly exposure. The FDA-approved label for alendronate confirms that 70 mg weekly provides the same BMD gains as 10 mg daily. This switch does not constitute dose escalation.

Is There Evidence for Higher Doses?

Short answer: no. The FIT trial tested 5 mg and 10 mg daily. The 10-year FLEX extension continued the 10 mg or 5 mg arms. No published RCT has tested alendronate at doses above 10 mg daily (or 70 mg weekly) for postmenopausal osteoporosis. Doses of 40 mg daily are approved only for Paget disease of bone, and extrapolating Paget dosing to osteoporosis carries increased risk of esophageal irritation, hypocalcemia, and atypical femur fracture without established fracture-reduction benefit.

Switching Formulations

For patients with confirmed GI intolerance or suspected malabsorption, an effervescent buffered alendronate formulation (Binosto) provides the same 70 mg weekly dose but may improve tolerability. No evidence suggests it overcomes a true efficacy plateau.

Structured Drug Holidays: When and How to Pause

The concept of a bisphosphonate drug holiday emerged from the recognition that prolonged use (beyond 5 years for oral agents) increases the risk of rare but serious adverse events, specifically atypical femoral fractures (AFFs) and osteonecrosis of the jaw (ONJ).

Who Qualifies for a Drug Holiday

The 2017 American Society for Bone and Mineral Research (ASBMR) task force report and the 2020 AACE/ACE guideline recommend drug holidays primarily for patients at moderate fracture risk after 5 or more years of oral bisphosphonate therapy. "After five years of oral bisphosphonate therapy, clinicians should reassess fracture risk. For patients not at high risk, a drug holiday of up to five years is reasonable," the ASBMR task force concluded.

Patients who should NOT take a drug holiday include:

• T-score still below -2.5 at the hip after 5 years of treatment
• History of vertebral or hip fracture during treatment
• High FRAX score (10-year major osteoporotic fracture probability greater than 20%)
• Ongoing glucocorticoid use

Monitoring During the Holiday

During a drug holiday, BMD should be measured by DXA every 2 to 3 years. Bone turnover markers (CTX, P1NP) can be checked annually. A rising CTX above pretreatment levels or a BMD decline of 3 to 5% at the total hip signals the need to restart therapy. The residual effect of alendronate in bone matrix provides continued fracture protection for approximately 2 to 3 years after discontinuation, based on the FLEX trial data showing that women who discontinued alendronate after 5 years maintained stable hip BMD for 5 additional years, though lumbar spine BMD declined modestly (approximately 2 to 4% over 5 years).

When to Switch: Alternatives After Alendronate Plateau

For patients experiencing a genuine efficacy plateau or treatment failure (new fracture on therapy, significant BMD decline despite confirmed adherence), switching drug classes is appropriate.

Denosumab (Prolia) as a Step-Up

Denosumab 60 mg subcutaneous every 6 months provides continued BMD gains that do not plateau in the same way bisphosphonates do. The FREEDOM trial (N=7,868) showed continuous lumbar spine BMD increases of 9.2% at 3 years and, in the FREEDOM Extension, up to 21.7% at 10 years. For patients switching from alendronate, the STAND trial demonstrated that transitioning to denosumab produced significantly greater BMD gains at the total hip (1.90% vs. 1.05%, P<0.001) and lumbar spine (3.03% vs. 1.85%, P<0.001) compared with continuing alendronate over 12 months.

A critical caveat: stopping denosumab triggers rapid bone loss and potential rebound vertebral fractures. Patients who discontinue denosumab must be transitioned to a bisphosphonate.

Anabolic Agents: Teriparatide and Romosozumab

For patients with very high fracture risk, anabolic therapy may be the better next step.

Teriparatide (Forteo) 20 mcg daily subcutaneous for up to 2 years builds new bone rather than simply slowing resorption. The Fracture Prevention Trial (N=1,637) showed a 65% reduction in new vertebral fractures and 53% reduction in nonvertebral fractures. Teriparatide is typically followed by an antiresorptive agent (bisphosphonate or denosumab) to maintain gains.

Romosozumab (Evenity) 210 mg subcutaneous monthly for 12 months is the newest anabolic option. The ARCH trial (N=4,093) showed that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared with alendronate alone at 24 months. Romosozumab carries a cardiovascular warning and is contraindicated in patients who have had a myocardial infarction or stroke within the preceding year.

Zoledronic Acid: The IV Bisphosphonate Alternative

For patients who prefer less frequent dosing or have GI contraindications, zoledronic acid (Reclast) 5 mg IV once yearly is an option. The HORIZON-PFT trial (N=7,765) demonstrated a 70% reduction in vertebral fractures and 41% reduction in hip fractures over 3 years. Switching from oral alendronate to annual zoledronic acid is not truly dose escalation within the same mechanism, but the IV route bypasses GI absorption issues entirely.

Decision Framework: Step-by-Step Plateau Management

A practical approach to managing a suspected alendronate plateau follows this sequence.

Step 1: Confirm the Plateau Is Real

Review DXA trends across at least two measurement points. A BMD change within the precision error of the machine (typically 1 to 2% at the spine, 1.5 to 2.5% at the hip) is not a meaningful decline. Compare the same skeletal site on the same DXA machine.

Step 2: Rule Out Correctable Causes

Check adherence (direct questioning, pharmacy refill records), check CTX to verify resorption suppression, draw vitamin D and PTH, and screen for secondary causes as outlined above.

Step 3: Assess Total Duration and Fracture Risk

For patients on alendronate for 5 or more years who are at moderate risk: consider a drug holiday with DXA monitoring every 2 to 3 years. For patients at high risk (T-score below -2.5 at the hip, prior fracture, high FRAX): continue therapy or switch agents.

Step 4: Choose the Right Switch

• Moderate-risk plateau with GI issues: switch to zoledronic acid 5 mg IV yearly
• True treatment failure (fracture on therapy): consider anabolic-first strategy (romosozumab 12 months or teriparatide 18 to 24 months, followed by an antiresorptive)
• Continued BMD decline despite confirmed adherence: switch to denosumab 60 mg every 6 months

Long-Term Monitoring After Any Strategy Change

Regardless of the chosen approach, monitoring remains the constant. DXA scanning every 1 to 2 years during active treatment reassessment is recommended by the ISCD (International Society for Clinical Densitometry) 2019 position statement. Bone turnover markers (CTX for resorption, P1NP for formation) can provide earlier signal than DXA alone, often showing changes within 3 to 6 months of a therapy switch.

What Counts as a Successful Response

The NOF (National Osteoporosis Foundation) Clinician's Guide defines a successful response as stable or increasing BMD plus no new fractures. BMD does not need to rise continuously. Stability at a higher level than untreated baseline is the goal. Dr. Felicia Cosman, professor of medicine at Columbia University and co-author of the NOF guidelines, has noted: "We need to stop thinking of osteoporosis treatment as a race to a number. Stability is success."

Restarting After a Drug Holiday

If BMD declines significantly during a drug holiday (greater than 3 to 5% at total hip) or a new fracture occurs, restart the same bisphosphonate or switch to an alternative agent. There is no washout period required before restarting alendronate after a holiday.